

Special Issue

Liquid Biopsy of Genitourinary Tumors

Message from the Guest Editors

In our view, this Special Issue titled “Liquid Biopsy in Genitourinary Tumors” is timely. It is worth mentioning that both diagnostics and treatment of cancers, in general, have greatly benefited from the discovery of biomarkers through multi-omics and other technologies. The specimens from patients for analysis traditionally included biopsy tissues. Later, this was expanded to include blood (sera and plasma) and urine. The liquid biopsy, as is known, includes specimens from multiple sources such as blood, urine, saliva and cerebrospinal fluid (CSF). The components for analysis range from cells, exosomes, circulating cell-free DNA, RNA proteins, peptides and metabolites. The rationale for the analysis of body fluids from patients is that the analytical components may serve as biomarkers of the disease and disease status in real time, e.g., post-treatment follow-up. In addition, biomarkers can also serve as targets for treatment. It is our aim that this Special Issue will publish articles authored by investigators highlighting the recent advances in genitourinary tumors from both diagnostic and treatment perspectives.

Guest Editors

Prof. Dr. Ghulam Nabi

Dr. Alagarsamy Srinivasan

Prof. Dr. Sundarasamy Mahalingam

Dr. Shiv Srivastava

Deadline for manuscript submissions

closed (20 May 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/139224

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)